Global R&D Pipeline
My Favorite
Hot Targets:
APP (Aβ)
Back
Total number of drugs
369
Phase II and later clinical stages
11.4%
Involving companies
432
Main therapeutic areas
Nervous System Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Remternetug | Remternetug | Monoclonal antibody | Nervous System Diseases Other Diseases | APP inhibitors | Eli Lilly & Co. | Eli Lilly & Co. | Phase 3 | Phase 3 | - | - | - | Breakthrough Therapy（China） | - | - | - | - | Remternetug | - | - | detail > | |
| Florapronol (18F) | Florapronol (18F) | Small molecule drug Diagnostic radiopharmaceuticals | Nervous System Diseases | APP modulators | Korea Institute of Radiological & Medical Sciences | Korea Institute of Radiological & Medical Sciences | Approved | - | - | - | - | - | - | - | 18 F | - | Florapronol (18F) | - | - | detail > | |
| Scyllitol | Scyllitol | Small molecule drug | Nervous System Diseases | APP inhibitors | Transition Therapeutics, Inc. | Transition Therapeutics, Inc. | Phase 3 | - | - | - | - | - | - | - | - | - | Scyllitol | - | - | detail > | |
| (-)-Epigallocatechin Gallate | (-)-Epigallocatechin Gallate | Small molecule drug | Nervous System Diseases Congenital Disorders Skin and Musculoskeletal Diseases Other Diseases Neoplasms Digestive System Disorders Immune System Diseases Infectious Diseases Cardiovascular Diseases Mouth and Tooth Diseases Respiratory Diseases | APP inhibitors DYRK1A inhibitors LOXL2 inhibitors α-synuclein inhibitors | Charité - Universitätsmedizin Berlin | Merdury Biopharmaceutical Corporation Zunyi Medical University The University of Texas Southwestern Medical Center Nanchang University Universidad de Guanajuato University of California, Los Angeles Pharmasset, Inc. Quanzhou Maternal and Child Health Hospital | Phase 3 | Preclinical | - | - | - | Orphan Drug（United States） | - | - | - | - | (-)-Epigallocatechin Gallate | - | - | detail > | |
| Trontinemab | Trontinemab | Bispecific antibody | Nervous System Diseases | APP inhibitors TfR1 antagonists | F. Hoffmann-La Roche Ltd. | Genentech, Inc. Roche Holding AG Hoffmann-La Roche, Inc. F. Hoffmann-La Roche Ltd. | Phase 3 | Phase 3 | - | - | - | - | - | - | - | - | Trontinemab | - | - | detail > | |
| Ibuprofen/Sodium Cromoglicate | Ibuprofen/Sodium Cromoglicate | Small molecule drug | Other Diseases | APP inhibitors | AZTherapies, Inc. | AZTherapies, Inc. | Phase 3 | - | - | - | - | - | - | - | - | - | Ibuprofen/Sodium Cromoglicate | - | - | detail > | |
| Donanemab-AZBT | Donanemab-AZBT | Monoclonal antibody | Nervous System Diseases Other Diseases | 3pE-modified Aβ inhibitors | Eli Lilly & Co. | Eli Lilly Nederland BV Eli Lilly Canada, Inc. Eli Lilly & Co. Eli Lilly Japan KK Eli Lilly Australia Pty Ltd. | Approved | Approved | United States China European Union Japan United Kingdom Australia Iceland Liechtenstein Norway | 2024-07-02 | 2024-12-17 | Breakthrough Therapy（China） Breakthrough Therapy（United States） Priority Review（China） Priority Review（United States） | - | - | - | - | Donanemab-AZBT | - | - | detail > | |
| Anselamimab | Anselamimab | Monoclonal antibody | Neoplasms Immune System Diseases Endocrinology and Metabolic Disease Hemic and Lymphatic Diseases Other Diseases | APP inhibitors | Caelum Biosciences, Inc. | Alexion Pharmaceuticals, Inc. 阿斯利康全球研发（中国）有限公司 Fortress Biotech, Inc. | Phase 3 | Phase 3 | - | - | - | Fast Track（United States） Orphan Drug（European Union） Orphan Drug（United States） Orphan Drug（Japan） | - | - | - | - | Anselamimab | - | - | detail > | |
| Lecanemab | Lecanemab | Monoclonal antibody | Nervous System Diseases Congenital Disorders Other Diseases | APP inhibitors | BioArctic AB | Eisai Co., Ltd. Eisai GmbH Biogen, Inc. Eisai, Inc. Biogen U.S. Corp. BioArctic AB Eisai Europe Ltd. | Approved | Approved | United States China European Union Japan United Kingdom Canada Australia United Arab Emirates Hong Kong Israel Iceland South Korea Liechtenstein Mexico Norway | 2023-01-06 | 2024-01-05 | Accelerated Approval（United States） Breakthrough Therapy（United States） Fast Track（United States） Innovative Licensing and Access Pathway（United Kingdom） Priority Review（China） Priority Review（Japan） Priority Review（United States） | - | - | - | - | Lecanemab | - | - | detail > | |
| SK-PC-B70M | SK-PC-B70M | Small molecule drug | Nervous System Diseases | APP modulators | SK BIOPHARMACEUTICALS CO LTD | SK BIOPHARMACEUTICALS CO LTD | Phase 3 | - | - | - | - | - | - | - | - | - | SK-PC-B70M | - | - | detail > |
Total 369 data
1
2
3
4
5
6
...
36
37
